AU2003302235A1 - Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof - Google Patents

Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof

Info

Publication number
AU2003302235A1
AU2003302235A1 AU2003302235A AU2003302235A AU2003302235A1 AU 2003302235 A1 AU2003302235 A1 AU 2003302235A1 AU 2003302235 A AU2003302235 A AU 2003302235A AU 2003302235 A AU2003302235 A AU 2003302235A AU 2003302235 A1 AU2003302235 A1 AU 2003302235A1
Authority
AU
Australia
Prior art keywords
conjugates
preparation
methods
specific antigens
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302235A
Other languages
English (en)
Other versions
AU2003302235A8 (en
Inventor
Samuel J. Danishefsky
Vadim Dudkin
Xudong Geng
Mihirbaran Mandal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2003302235A8 publication Critical patent/AU2003302235A8/xx
Publication of AU2003302235A1 publication Critical patent/AU2003302235A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2003302235A 2002-12-03 2003-12-03 Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof Abandoned AU2003302235A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43082202P 2002-12-03 2002-12-03
US60/430,822 2002-12-03
US50016103P 2003-09-04 2003-09-04
US60/500,161 2003-09-04
US50070803P 2003-09-05 2003-09-05
US60/500,708 2003-09-05
PCT/US2003/038471 WO2004050711A2 (en) 2002-12-03 2003-12-03 Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof

Publications (2)

Publication Number Publication Date
AU2003302235A8 AU2003302235A8 (en) 2004-06-23
AU2003302235A1 true AU2003302235A1 (en) 2004-06-23

Family

ID=32475412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302235A Abandoned AU2003302235A1 (en) 2002-12-03 2003-12-03 Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof

Country Status (6)

Country Link
US (1) US7531181B2 (https=)
EP (1) EP1569955A2 (https=)
JP (1) JP2006514981A (https=)
AU (1) AU2003302235A1 (https=)
CA (1) CA2508539A1 (https=)
WO (1) WO2004050711A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) * 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE60027905T2 (de) 1999-08-20 2007-05-10 Sloan-Kettering Institute For Cancer Research Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
WO2004050711A2 (en) 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
WO2005078443A1 (en) * 2004-02-13 2005-08-25 Inverness Medical Switzerland Gmbh Determination of infection by the immune response to a carbohydrate moiety
KR20080056688A (ko) * 2005-03-16 2008-06-23 유니버시티 오브 옥스퍼드 Ｈｉｖ－ｉ용 만노스 면역원
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
EP2010556B1 (en) 2006-04-11 2015-09-23 Sloan-Kettering Institute for Cancer Research Homogeneous erythropoietin and method for their preparation
TWI432448B (zh) * 2006-09-14 2014-04-01 Univ Duke 疫苗
KR20090103939A (ko) * 2007-01-29 2009-10-01 유나이티드 세러퓨틱스 코오포레이션 당 면역원
ES2360334T3 (es) 2008-06-27 2011-06-03 Theranor Sprl Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus.
EP2315771A4 (en) 2008-07-11 2012-02-01 Sloan Kettering Inst Cancer GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF
US20110136729A1 (en) * 2009-05-26 2011-06-09 Shien Lu Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
US9493580B2 (en) 2010-06-11 2016-11-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
EP2925774B8 (en) 2012-11-29 2018-03-07 The Texas A&M University System Engineering the production of a conformational variant of occidiofungin that has enhanced inhibitory activity against fungal species
EP3191114B1 (en) 2014-09-12 2021-03-03 Mississippi State University Occidiofungin formulations and uses thereof
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (pt) 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US7556806B2 (en) * 2002-10-11 2009-07-07 University Of Maryland Biotechnology Institute Carbohydrate-based synthetic vaccines for HIV
WO2004050711A2 (en) 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
AU2003302165A1 (en) 2002-12-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.

Also Published As

Publication number Publication date
CA2508539A1 (en) 2004-06-17
EP1569955A2 (en) 2005-09-07
US7531181B2 (en) 2009-05-12
JP2006514981A (ja) 2006-05-18
WO2004050711A3 (en) 2005-01-27
WO2004050711A2 (en) 2004-06-17
AU2003302235A8 (en) 2004-06-23
US20060229432A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
AU2003302235A1 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
AU2003299819A1 (en) Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
AU2002251913A1 (en) Hybrid antibodies and uses thereof
AU2003253048A1 (en) Tubulysin conjugates
AU2002351623A1 (en) Streptococcus antigens
AU2001289684A1 (en) Glass-ceramics, process for their preparation and use
AU2002354929A1 (en) Antibodies specific for nanotubes and related methods and compositions
AU2003265576A1 (en) Corticosteroid conjugates and uses thereof
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2003276247A1 (en) Phthalimidyl-azo dyes, process for their preparation and their use
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003224313A1 (en) Mycobacterial antigens and uses thereof
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2004003149A8 (en) Cngh0005 polypeptides, antibodies, compositions, methods and uses
WO2005065382A8 (en) Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
AU2001251394A1 (en) Immunological methodology for discerning human papillomavirus
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
AU2003267361A1 (en) Orthopoxvirus antigens and use thereof
AU2000254308A1 (en) Pyrazolopyrimidinone derivatives, process for their preparation and their use
AU2003219696A1 (en) Sga-1m, a cancer associated antigen, and uses thereof
IL165779A0 (en) Steroid conjugate, preparation thereof and the usethereof
AU2002229870A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2002365925A1 (en) Rsv proteins, antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase